Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Provided By GlobeNewswire
Last update: May 8, 2025
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025
Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone)
Read more at globenewswire.comNASDAQ:CING (9/2/2025, 10:29:35 AM)
3.925
-0.07 (-1.63%)
NASDAQ:CINGW (9/2/2025, 9:54:40 AM)
0.07
+0.02 (+40%)
Find more stocks in the Stock Screener
